Addus Homecare

ADUS · NASDAQ

$118.03+$2.87 (+2.49%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $115.16

ADUS analyst rating

HoldConsensus of 7 analysts over the last 12 months. 57% rate it a buy.

Strong buy0
Buy4
Hold2
Underperform1
Sell0

12-month price target · 15 analysts

Average $136.37 (+15.5% upside)

Low: $96.96
Now: $118.03
High: $162.75

Upgrades and downgrades

The latest rating actions, newest first

ADUS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B of A Securities	Sep 14, 2026	Downgrade	Buy → Neutral	$140.00 → $125.00	53%
RBC Capital	Aug 5, 2026	Maintains	Outperform	$130.00 → $134.00	57%
Barclays	Jul 9, 2026	Maintains	Underweight	$92.00 → $96.00	59%
Citizens	May 18, 2026	Maintains	Market Outperform	$142.00	38%
Barclays	May 15, 2026	Maintains	Underweight	$102.00 → $92.00	59%
Citizens	May 6, 2026	Maintains	Market Outperform	$150.00 → $142.00	38%
Barclays	Mar 25, 2026	Maintains	Underweight	$112.00 → $102.00	59%
Stephens & Co.	Feb 25, 2026	Maintains	Overweight	$140.00 → $135.00	64%
Barclays	Feb 24, 2026	Maintains	Underweight	$117.00 → $112.00	59%
BMO Capital	Nov 13, 2025	Initiates	Market Perform	$120.00	41%

The case for and against

Updated Oct 16, 2026

Bull case

Addus HomeCare is attractive because its core Personal Care business is still producing healthy organic growth, with 1Q26 same-store revenue up 6.5%, billable hours up 5.2%, and margin expanding to 12.2% adjusted EBITDA. The company also appears well positioned for disciplined expansion after slowing M&A spend to $32M in 2025, then adding Helping Hands for $21M and additional Indiana operations in 2026 while holding $103M in cash versus $94M of total debt at the end of Q1. With expected 2026 EBITDA of $196M and free cash flow of $120M, plus a favorable federal and state regulatory backdrop, the business has room to grow through both operating leverage and accretive acquisitions.

Bear case

Addus HomeCare is exposed to concentrated policy and reimbursement risk, with more than 20% of revenue tied to Illinois CCP and meaningful sensitivity in Personal Care to state rate-setting and minimum wage changes that could compress margins. Federal Medicaid uncertainty, the Medicaid Access Rule’s “payment adequacy” provision effective in 2030, and any Medicare hospice or home health rate cuts could further pressure growth, especially given service margins north of 20% in some states. Operationally, Gentiva integration risk, along with weaker home health volumes and visits and only modest hospice revenue gains, suggests execution challenges that may keep fundamentals under strain.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.